Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;46(9):671-681.
doi: 10.1016/j.gastrohep.2022.10.021. Epub 2022 Nov 11.

Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

[Article in English, Spanish]
María Rocío Davis González  1 , María Pilar Ballester  2 , Eva Romero-González  1 , Ana María Sánchez-Pardo  1 , David Marti-Aguado  1 , Joan Tosca  1 , Carles Suria  1 , Rosario Antón Ausejo  1 , Isabel Pascual Moreno  1 , María Dolores Planelles Silvestre  3 , Miguel Mínguez Pérez  1 , Marta Maia Bosca-Watts  1
Affiliations

Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors

[Article in English, Spanish]
María Rocío Davis González et al. Gastroenterol Hepatol. 2023 Nov.

Abstract

Background: Loss-of-response and adverse events (AE) to biologics have been linked to HLA-DQA1*05 allele. However, the clinical factors or biologic used may influence treatment duration. Our objective was to evaluate the influence of clinical and therapeutic factors, along with HLA, in biological treatment discontinuation.

Methods: A retrospective study of consecutive IBD patients treated with biologics between 2007 and 2011 was performed. Main outcome was treatment discontinuation due to primary non-response (PNR), secondary loss of response (SLR) or AE. HLA-DQA1 genotyping was done in all patients. Regression analyses were used to assess risk factors of treatment discontinuation.

Results: One hundred fifty patients (61% male) with 312 biologic treatments were included. 147 (47%) were discontinued with a cumulative probability of 30%, 41% and 56% at 1, 2 and 5 years. The use of infliximab (p=0.006) and articular manifestations (p<0.05) were associated with treatment discontinuation. Considering cause of withdrawal, Ulcerative Colitis (UC) had a higher proportion of PNR (HR=4.99; 95% CI=1.71-14.63; p=0.003), SLR was higher if biologics had been indicated due to disease flare (HR=2.32; 95% CI=1.05-5.09; p=0.037) while AE were greater with infliximab (HR=2.46; 95% CI=1.48-4.08; p<0.001) or spondylitis (HR=2.46; 95% CI=1.78-6.89; p<0.001). According to the biological drug, HLA-DQA1*05 with adalimumab showed more SLR in cases with Crohn's disease (HR=3.49; 95% CI=1.39-8,78; p=0.008) or without concomitant immunomodulator (HR=2.8; 95% CI=1.1-6.93; p=0.026).

Conclusions: HLA-DQ A1*05 was relevant in SLR of IBD patients treated with adalimumab without immunosupression. In patients treated with other biologics, clinical factors were more important for treatment interruption, mainly extensive UC or extraintestinal manifestations and having indicated the biologic for flare.

Keywords: Adverse events; Biological drugs; Biológicos; Efectos adversos; Enfermedad inflamatoria intestinal; HLA-DQ A1*05; HLA-DQA1*05; Inflammatory bowel disease; Pérdida secundaria de respuesta; Secondary loss of response.

PubMed Disclaimer